ABVC BioPharma Achieves $100,000 Licensing Milestone with ForSeeCon, Enhancing Ophthalmology Innovations
July 18th, 2025 1:00 PM
By: Newsworthy Staff
ABVC BioPharma's recent $100,000 milestone payment from ForSeeCon Eye Corporation underscores the growing commercial interest in their ophthalmology solutions, particularly Vitargus®, and strengthens their position in the global eye care market.
ABVC BioPharma, Inc. has announced the receipt of a $100,000 milestone licensing payment from ForSeeCon Eye Corporation, marking a significant step in their collaboration to develop and commercialize drugs for ophthalmic indications. This payment increases ABVC's cumulative licensing revenue to $946,000, with the potential for the overall value of their agreements to reach up to $1.0 billion. The partnership focuses on Vitargus®, a next-generation vitreous substitute, targeting the expansive global eye care market, projected to reach $110.3 billion by 2030.
Dr. Uttam Patil, ABVC's Chief Executive Officer, highlighted the importance of this milestone as a reflection of the company's commitment to innovation in ophthalmology and a source of non-dilutive capital for future development phases. Mr. Jerry Chang, CEO of ForSeeCon Eye Corporation, expressed enthusiasm for the global response to Vitargus® and the potential to improve retinal surgery outcomes. The companies plan to initiate pivotal clinical trials in key international markets in 2025, supported by this latest payment and the momentum from previous licensing deals and revenue growth.
For more information on the global eye care market, visit https://www.grandviewresearch.com/horizon/outlook/eye-care-market-size/global?utm_source=chatgpt.com.
Source Statement
This news article relied primarily on a press release disributed by NewMediaWire. You can read the source press release here,
